What was published
On 19 October 2026, PMDA posted Japanese and English Early Consideration on parallel development of anticancer medicines and companion diagnostics. The document itself is dated 5 October.
Why it matters
Targeted medicines may depend on a genomic alteration or biomarker. If the test is not ready when the medicine reaches practice, appropriate patient selection becomes difficult. Coordinating both development pathways is therefore central to precision oncology.
Status: Early Consideration for developers. This is not approval of a medicine or diagnostic and does not establish efficacy for any product.
What comes next
Real patient access depends on product-specific trials, applications, approvals, labelling and reimbursement.